

1    **Molecular PD-L1 PET/CT Imaging with <sup>89</sup>Zr-atezolizumab to Monitor Immune**  
2    **Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II**  
3    **diagnostic imaging trial.**

4    Short title: <sup>89</sup>Zr-atezolizumab PET-imaging in metastatic triple negative breast cancer

5  
6    Renske Altena <sup>1,2\*</sup>, Thuy A. Tran <sup>2,3</sup>, Una Kjällquist <sup>1,2</sup>, Mattias Karlsson <sup>4</sup>, Jonathan Siikanen <sup>3</sup>, Emma  
7    Jussing <sup>2,3</sup>, Antonios Tzortzakakis <sup>4,5</sup>, Olof Jonmarker <sup>5,6</sup>, Rimma Axelsson <sup>4,7</sup>, Jonas Bergh <sup>1,2</sup>

8  
9    **Author affiliations**

10    1. Medical Unit Breast, Endocrine Tumors and Sarcoma, Theme Cancer, Karolinska University Hospital,  
11    Stockholm, Sweden.

12    2. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

13    3. Department of Radiopharmacy, Karolinska University Hospital, Solna, Sweden

14    4. Department of Medical Radiation Physics and Nuclear Medicine, Functional Unit of Nuclear  
15    Medicine, Karolinska University Hospital, Huddinge, Sweden

16    5. Division of Radiology, Department for Clinical Science, Intervention and Technology (CLINTEC),  
17    Karolinska Institutet

18    6. Department of Radiology, Functional Unit of Medical Diagnostics, Karolinska University Hospital,  
19    Solna, Sweden

20    7. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

21

22    \* Correspondence: Renske Altena MD PhD, Medical Unit Breast, Endocrine tumors and Sarcoma,

23    Karolinska University Hospital Solna, Sweden, Email: [renske.altena@ki.se](mailto:renske.altena@ki.se), Telephone: +46 8 123 755

24    18

25

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 26 **Abstract**

### 27 **Background**

28 Immune checkpoint inhibitors (Programmed Death Ligand 1 [PD-L1] and Programmed Death 1 [PD-1]  
29 antibodies) are approved for the first line treatment of metastatic and irresectable triple negative  
30 breast cancer (mTNBC) with immunohistochemical (IHC) PD-L1 positivity on a tumor biopsy, and  
31 combined with a chemotherapy backbone. Intra- and interlesional as well as spatial heterogeneity in  
32 PD-L1 expression as well the invasive nature of tumor biopsies poses disadvantages of this method of  
33 selecting patients for the addition of PD-L1/PD-1 antibodies. Our study hypothesis is that whole body  
34 Positron Emission Tomography with computed tomography (PET/CT) imaging with a PD-L1 specific  
35 radiotracer could be a more reliable biomarker approach for the selection of patients with mTNBC  
36 who benefit from the addition from PD-L1/PD-1 antibodies.

37

### 38 **Methods**

39 In the phase II “Molecular PD-L1 PET/CT Imaging with <sup>89</sup>Zr-atezolizumab to Monitor Immune  
40 Responses in metastatic Triple Negative Breast Cancer” (MIMIR-mTNBC) trial, treatment enrichment  
41 for checkpoint inhibitors is done by a baseline <sup>89</sup>Zr-atezolizumab PET/CT followed by a tumor biopsy to  
42 determine PD-L1 by IHC. Patients with a PD-L1 positive tumor on biopsy and/or PET are treated with  
43 chemotherapy + atezolizumab. The primary aim of the study is to assess the level of statistical  
44 agreement between the reference standard (PD-L1 IHC) compared to the experimental method (PD-  
45 L1 PET) by means of Cohen’s kappa coefficient. The trial is registered at Clinicaltrials.org with number  
46 NCT05742269.

47

### 48 **Discussion**

49 The results of the MIMIR-mTNBC trial are expected to reveal the possibility of PD-L1 PET with <sup>89</sup>Zr-  
50 atezolizumab to complement or replace the assessment of PD-L1 status by means of IHC on a tumor  
51 biopsy, and as a possible method to select patients with mTNBC that benefit from the addition of

52 atezolizumab to a chemotherapy backbone. This non-invasive tool may provide a method that reveals  
53 relevant information about heterogeneity in the expression of the target of treatment.

54

55 **Trial registration:** NCT05742269, Trial registered on February 23<sup>rd</sup>, 2023, at [clinicaltrials.gov](https://clinicaltrials.gov)

56 **Keywords:** Metastatic triple negative breast cancer, PD-L1, <sup>89</sup>Zr-atezolizumab, molecular imaging,  
57 predictive biomarker

58 **Data Availability:** All relevant data needed to replicate the trial can be found in the study protocol and  
59 through communication with the Principal Investigator.

60 **Funding:** This study is funded by a grant from the Swedish Cancer Society (Dnr 19 0189 Us) to  
61 Professor Jonas Bergh, Radiumhemmets Research Fund 2020 to Renske Altena, Swedish Breast cancer  
62 Society 2020 to Renske Altena and Percy Falk Foundation to Professor Rimma Axelsson. Atezolizumab,  
63 SP142 IHC antibodies and Foundation One CDx is kindly provided by Roche AB. The funders do not  
64 have a direct role in the design of the study and collection, analysis, or interpretation of data.

65 **Competing interests:** The authors have declared that no competing interests exist.

66

67

68

69 Word count (core text) 3,567

70 References 18

71 Figures 2

72 Tables 2

73

74

75

## 76 Introduction

77 The current standard of care for triple negative breast cancer includes the combination of immune  
78 checkpoint inhibitors (ICI) with a chemotherapy backbone, both in the neo-adjuvant and metastatic  
79 setting. For patients with metastatic or irresectable triple negative breast cancer (mTNBC)  
80 atezolizumab (Programmed Death Ligand 1 [PD-L1]) and pembrolizumab (anti Programmed Death [PD-  
81 1]) are approved for patients with immunohistochemical (IHC) PD-L1 expression in a tumor biopsy  
82 according to specific criteria with a companion diagnostic IHC antibody, based on data from the  
83 IMpassion130 and Keynote355 trials respectively (1-4).

84  
85 In the IMpassion130 study, patients with mTNBC were treated with nab-paclitaxel atezolizumab or  
86 placebo. A statistically significant improvement in progression free survival (PFS) and a clinically  
87 meaningful improvement in overall survival (OS) for patients whose tumor had over 1% PD-L1  
88 expression on tumor infiltrating lymphocytes was found, with a numeric improvement in median PFS  
89 of 2.5 months (7.5 months and 5.0 months, respectively with a hazard ratio [HR] of 0.62; 95%  
90 confidence interval [CI] 0.49-0.78;  $P < 0.001$ ) and a median OS of almost 10 months (25.0 months and  
91 15.5 months, respectively, with a HR of 0.62; 95% CI, 0.45-0.86) (1,2). At the final OS update, this  
92 benefit in overall survival landed at 7.5 months in the PD-L1 positive subgroup (HR, 0.67; 95% CI, 0.53-  
93 0.86) (2).

94 In the Keynote355 study, patients with a Combined Positive Score (CPS with the pharmDx test) of 10  
95 or more treated with pembrolizumab plus chemotherapy (either nab-paclitaxel; paclitaxel; or  
96 gemcitabine plus carboplatin) had an improvement in median PFS of little over 4 months (9.7 months  
97 and 5.6 months respectively, HR for progression or death, 0.65, 95% CI 0.49–0.86) (3), and an increase  
98 in OS for patients in the CPS-10 subgroup was from 16.1 months in the placebo–chemotherapy group  
99 to 23.0 months in the pembrolizumab–chemotherapy group (hazard ratio for death, 0.73; 95% CI  
100 0.55-0.95) (4).

101

102 There is an urgent clinical need to establish reliable and reproducible therapy-predictive biomarkers  
103 for ICI in solid tumors, in order to optimize the risk-benefit balance on an individual and societal level.  
104 Up to now, for mTNBC the only approved biomarker for the addition of ICI to a chemotherapy  
105 backbone is PD-L1 expression on a tumor biopsy according to pre-defined criteria as mentioned above  
106 [5]. However, this method also has a suboptimal performance, as concluded in a systematic review  
107 and meta-analysis across all solid tumors [6]. For TNBC, several alternative candidate biomarkers have  
108 been proposed but have yet to be validated thoroughly enough to be implemented in clinical practice  
109 and replace PD-L1 IHC on a tumor biopsy [7]. It has been unequivocally described that PD-L1  
110 expression can change over time in primary and metastatic breast cancer, as well as have varying  
111 levels of expression in metastases in different organs [8], which limits even further the therapy-  
112 predictive role of PD-L1 IHC for the benefit of ICIs for patients with TNBC. Interestingly, PD-L1 status in  
113 the primary tumor has no therapy-predictive role for the addition of pembrolizumab to a  
114 chemotherapy backbone in the neoadjuvant treatment setting, as was observed in the Keynote522  
115 trial [9].  
116  
117 Positron Emission Tomography (PET) imaging with receptor-specific tracers can provide, in a non-  
118 invasive manner, information on whether the target for treatment exists. At the same time, PET  
119 enables quantification of the target in the whole body in real-time and with a high degree of accuracy.  
120 Several radiotracers representing treatment targets in breast cancer management have been  
121 evaluated, e.g. tracers visualizing the Estrogen Receptor (ER) and Human Epidermal growth factor  
122 Receptor 2 (HER2).  $^{18}\text{F}$ -FES, representing ER-positive lesions, is a currently FDA approved tracer that  
123 can be used in combination with a tumor biopsy to determine ER status in the whole body (10).  
124 A few radiotracers representing targets of ICIs, or their downstream intracellular effects, have been  
125 studied [11]. The first study published is a first-in-human study with  $^{89}\text{Zr}$ -atezolizumab in 25 patients  
126 (NCT02453984), including four patients with mTNBC [12]. This study showed that imaging with the  
127 tracer was feasible and safe. The results indicated clear heterogeneity of expression within and

128 between lesions and a promising role as a predictive marker for response to treatment with PD-L1  
129 antibodies. For the patients with mTNBC in this study, SUVmax was clearly over the SUVmean in the  
130 blood pool measured over the aorta, with varying levels of SUVmax in different organs. In this study,  
131 higher SUVmax was related to a better antitumor response, according to RECIST.

132

133 Here we report the study protocol of the Molecular Imaging to Monitor Immune Responses in mTNBC  
134 (MIMIR-mTNBC; EU CT 2022-500808-21-00, NCT05742269) trial. In this phase II diagnostic imaging  
135 study, we aim to evaluate the role of <sup>89</sup>Zr-atezolizumab PET/CT as a way to refine the group of patients  
136 with mTNBC that benefit from the addition of an ICIs to a chemotherapy backbone. The primary  
137 purpose of the trial is to establish the level of statistical agreement between PD-L1 status by the  
138 current reference standard with IHC versus PET with <sup>89</sup>Zr-atezolizumab. Our hypothesis is that Positron  
139 Emission Tomography combined with Computed Tomography (PET/CT) imaging with a contemporary  
140 radiotracer (<sup>89</sup>Zr-atezolizumab), visualizing PD-L1 expression in the whole body, could be a better  
141 predictive biomarker to select which patients benefit from ICI.

142

143

144

145

146

## 147 **Materials and methods**

148 To test this hypothesis, we are performing a phase II PD-L1 PET/CT imaging study with <sup>89</sup>Zr-  
149 atezolizumab in patients with mTNBC. The study design is summarized as SPIRIT schedule of  
150 enrolment, interventions and assessments in Figure 1. A graphical representation of the study design  
151 is presented in Figure 2.

152

### 153 **Study setting**

154 Our target population consists of patients with mTNBC scheduled for first line palliative systemic  
155 treatment with nab-paclitaxel and carboplatin. This chemotherapy combination is used to maximize  
156 the therapeutic potential of this first line systemic treatment line, extrapolating signals from early  
157 TNBC (13) and in the absence of signs that indicate augmented safety issues (14).

158 Patients will be recruited at Karolinska University Hospital in Stockholm, Sweden. Additional Swedish  
159 study sites are planned to be added. The study-specific investigations with <sup>89</sup>Zr-atezolizumab PET/CT,  
160 the study biopsies and blood samples will be done at the respective sites. The <sup>89</sup>Zr-atezolizumab  
161 radiotracer will be centrally produced at the Department of Radiopharmacy, Karolinska University  
162 hospital in Solna, and shipped by courier to the respective sites throughout the country. The PD-L1 IHC  
163 will be centrally reviewed by the study pathologist that is dedicated to this study and trained and  
164 certified by Ventana on PD-L1 status assessment using SP142 and IHC. The PET-images will be  
165 acquired according to a standardized protocol that will be the same throughout all the sites and  
166 reviewed by a nuclear medicine physician <sup>89</sup>Zr-atezolizumab radiotracer.

167

### 168 **Study population**

169 Patients with metastatic/irresectable triple negative breast cancer are candidates for inclusion in the  
170 MIMIR-mTNBC trial, according to the inclusion and exclusion criteria summarized in Table 1. In short,  
171 patients must be fit and willing to receive treatment with chemotherapy plus/minus atezolizumab and  
172 undergo a tumor biopsy and PET/CT. The tumor localizations have to be measurable according to

173 RECIST v1.1 (14) and a non-skeletal lesion has to be accessible for ultrasound- or CT-directed biopsy.  
174 No contra-indications for PET/CT investigations or treatment with atezolizumab must be present.  
175 Informed consent is mandatory before randomization and will be obtained by a physician with the  
176 appropriate delegation.

177

## 178 **Experimental investigations**

179 Study-related assessments include imaging, laboratory tests (blood, feces and tumour samples) and  
180 clinical outcome assessments including treatment response and toxicities, as summarized in the SPIRIT  
181 chart in Figure 1.

182

### 183 *1. Imaging Assessments*

184 The participants of the study will undergo one session of <sup>89</sup>Zr-atezolizumab PET/CT (PD-L1 PET in the  
185 rest of this manuscript), which is performed within 14 days before initiation of the systemic  
186 oncological treatment. Response evaluation after 2 courses of systemic therapy will be performed  
187 according to clinical routine with CT of chest and abdomen.

188

189 <sup>89</sup>Zr-atezolizumab is administered as a single intravenous injection at the department of Nuclear  
190 Medicine. Pre-injection as well as one hour after injection, blood pressure, pulse and temperature are  
191 taken by a nurse experienced with the administration of radiotracers. The patient can go home  
192 afterwards and will be phoned by the study nurse 48-72 hours later to follow-up clinical status.

193

194 At 5 days post-injection of <sup>89</sup>Zr-atezolizumab, a whole-body PET will be acquired. Imaging will be  
195 performed using the same protocol on either a Siemens Biograph mCT PET/CT scanner (Siemens,  
196 Erlangen, Germany) or GE Discovery MI, (GE, Milwaukee, WI, USA) at participating sites (according to  
197 2.4). The images acquired using PD-L1 PET will be analyzed with image processing software available in



198 the clinic (Syngo.Via, Siemens Healthineers and Software from Hermes Medical Solution AB, Sweden),  
199 according to the following steps:

200 1) At the imaging day, a first examination will be done to assess whether <sup>89</sup>Zr-atezolizumab PD-L1 positive lesions  
201 are found. This will be communicated with the study interventional radiologist who then decides the optimal  
202 location to obtain the study specific tumor biopsy.

203  
204 2) The maximum, peak, and average standardized uptake value (SUVmax, SUV peak, and SUVmean), and Total  
205 PD-L1 Positive Volume) will be estimated in the whole-body images acquired and will be analysed after all  
206 patients have been included and results for the final analysis are prepared.

207

208 2. *Biological material: tumor, blood and feces samples*

209 Tumor biopsy for PD-L1: Within 72 hours after the PD-L1 PET scanning, one or more tumour biopsies  
210 are obtained from metastatic lesion (-s). Core biopsy needles are used to increase chances to obtain  
211 representative material and to minimize the change for sample bias due to spatial heterogeneity in  
212 PD-L1 expression. The biopsy is performed by an experienced radiologist and will be image-guided  
213 with either ultrasound- or CT-directed modalities. The site of biopsy is determined by the radiologist  
214 and guided by the fused images obtained from the PD-L1 PET Investigation. Preferentially, material  
215 should be obtained from a lesion that shows PD-L1 positivity. In case of presence of both PD-L1  
216 positive and PD-L1 negative lesions at the PD-L1 PET, when technically feasible and deemed safe by  
217 the radiologist, material is obtained from both a positive and a negative lesion. When available,  
218 material from the primary tumor is retrieved by the pathologist for review and to perform PD-L1 IHC.

219

220 The biopsied material is transported to the pathology department at the hospital where the biopsy is  
221 taken and managed according to clinical routine. Material from the primary tumor (when available) is  
222 collected. The Ventana SP142 antibody is used to assess PD-L1 status, where PD-L1 positivity is  
223 defined as positive PD-L1 expression on  $\geq 1\%$  of immune cells.

224 After performing IHC, whole slide PD-L1 stained tissue/core biopsy sections, including a positive and  
225 negative control, are scanned by 40x magnification (Hamamatsu or similar), and sent to the study  
226 pathologist for central revision.

227

228 Blood samples: Circulating PD-L1 mRNA: Exosomes are released from normal and from cancer cells,  
229 representing the phenotype of their originating cell by their content of RNA, DNA and proteins. PD-L1  
230 gene expression from exosomally derived RNA was performed by Raimondi et al (16), demonstrating  
231 that high levels of PD-L1 mRNA expression at baseline were correlated with greater response to  
232 atezolizumab plus nab-paclitaxel, and that partial or complete response was positively associated with  
233 decrease in mRNA expression and improved overall survival. In our study, exosomal mRNA expression  
234 will be performed with the same strategy using the exoRNeasy kit (Qiagen) and Bio-Rad QX100 ddPCR.

235

236 Foundation One Liquid CDx: Material for Foundation One liquid biopsy is collected at baseline and at  
237 the first therapy evaluation, 8 weeks after treatment start. FoundationOne CDx™ (Foundation  
238 Medicine, Penzberg Germany; FoundationOne Liquid Cdx test) FoundationOne Liquid CDx is a next  
239 generation sequencing based in vitro diagnostic device that analyses 324 genes. Substitutions and  
240 insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs)  
241 are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects  
242 tumor fraction and the genomic signatures blood tumor mutational burden (bTMB) and microsatellite  
243 instability high (MSI-H) status. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA)  
244 isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. For  
245 this sample, a separate informed consent form will be retrieved from the study participant.

246

247 Feces microbiome analyses: Feces samples are collected at baseline and at the first treatment  
248 evaluation after two 4-weekly treatment cycles. The aim of this project is to evaluate potential  
249 therapy-modifying factors verified from the gut microbiota. Several studies have shown that efficacy

250 of ICI treatment is influenced by the microbiome, e.g. the gastro-intestinal/colonic bacterial flora (17,  
251 18). Both pre-clinical as well as clinical data have shown that presence of certain forms of microbiome  
252 constitute as well as recent and current use of antibiotics are related to a lack of ICI treatment effect.  
253 Clinical data on antibiotic and proton pump inhibitor use will be monitored.

254

### 255 3. *Clinical Outcome Assessments*

256 All patients will undergo a baseline CT of the chest-abdomen to be able to perform a treatment  
257 evaluation after 2 courses (8 weeks) with the systemic therapy as defined above. In addition, routine  
258 blood tests are performed, at the discretion of the treating physician. For the PD-L1+ patients who are  
259 treated with atezolizumab, additional blood tests aimed at measuring toxicity from this drug will be  
260 performed aimed to detect signs of immune-mediated toxicities. A CT/MRI of the brain will be  
261 performed in case of a clinical suspicion for CNS metastases, or when PD-L1 positive lesion(s) are  
262 noted on the baseline PD-L1 PET scan.

263 Toxicity management, including supportive medication and dose reductions, is done at the discretion  
264 of the treating physician in conjunction with the Principal Investigator and according to the  
265 recommendations in the study protocol.

266

### 267 **Outcomes**

268 Objectives and endpoints are summarized in Table 2. The primary endpoint is the concordance  
269 between the current reference standard for PD-L1 testing (IHC on a tumor biopsy) and the  
270 experimental method (PD-L1 PET). Secondary endpoints are related to heterogeneity in PD-L1  
271 receptor expression and the therapy-predictive value of PD-L1 PET. Exploratory endpoints relate to  
272 detection of metastases in sanctuary sites such as the central nervous system, relation with circulating  
273 biomarkers and the possible relation with uptake on PD-L1 PET and the development of immune-  
274 mediated toxicity.

275

276 **Data management**

277 Data are registered using an electronic Case Report Form (eCRF). Monitoring is performed according  
278 to Good Clinical Practice (GCP) guidelines. The eCRF provides data on patient demographics, tumor  
279 biological and treatment characteristics, as well as and data on follow-up. Data are managed by the  
280 Clinical Trial Office at Centre for Clinical Cancer Studies, Karolinska University Hospital, Stockholm,  
281 Sweden. Recorded information is pseudonymised. The MIMIR-mTNBC trial is registered at  
282 [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT05742269). Ethical permission has been obtained by the Swedish Ethical  
283 Review Authority and Medical Product Agency (Dnr 5.1.1-2022-73437). All participants must provide  
284 their written informed consent to participate in this trial.

285

286 **Follow-up**

287 The trial ends for each participant followed for 30 days after disease progression but also for  
288 participants who die, withdraw consent, or are lost to follow-up.

289

290 **Sample size**

291 This is an exploratory phase II non-randomized study with the primary aim to assess the statistical  
292 agreement (by Cohen's kappa coefficient) between the current gold standard (PD-L1 IHC by SP142,  
293 where PD-L1 positivity is defined as expression  $\geq 1\%$  on immune cells) and the experimental method  
294 with PD-L1 PET (PD-L1 positivity is defined as having at least one lesion with radiotracer uptake over  
295 the background uptake). Approximately 40% of cases are expected to have PD-L1 positivity by means  
296 of the reference standard with PD-L1 IHC, based on the data from the IMpassion130 and Keynote 355  
297 trials. We regard a kappa of 0.80 as having a very good statistical agreement; 64 patients are needed  
298 to be able to estimate the kappa with a precision of  $\pm 0.15$ .

299

300 **Statistical methods**

301 Continuous data will be summarized using descriptive statistics, where the following parameters will  
302 be reported: number of evaluable and missing observations, mean and standard deviation, median,  
303 quartiles, and extreme values (minimum and maximum) unless stated otherwise. Categorical data will  
304 be presented as number and percentage of subjects. Tests will be two-sided and performed at the 5%  
305 significance level unless stated otherwise. All eligible patients will be included in the analysis of the  
306 primary, secondary and exploratory objectives. The safety analysis set will contain all subjects who  
307 have been exposed to the investigational products <sup>89</sup>Zr-atezolizumab and atezolizumab.

308

### 309 **Independent safety analysis**

310 An Independent Data Monitoring Committee will execute the following monitoring plan and can  
311 recommend termination of the study based on the pre-defined stopping criteria. A patient will be  
312 withdrawn immediately if she/he withdraws informed consent at her/his own request, unacceptable  
313 toxicity occurs, not manageable by symptomatic therapy, dose delay or dose modification, she/he  
314 does not comply with the instructions given by the study personnel, pregnancy occurs, the medication  
315 has to be discontinued for medical reasons, including severe side effects, other disease, need of other  
316 cancer treatment. Patients who have been withdrawn will continue to be tracked and assessed (unless  
317 the patient explicitly declines). Entire trial: The study can be stopped due to Adverse Events whose  
318 frequency, severity or gravity justify discontinuation, as determined by the Principal Investigators.

319

### 320 **Time plan**

321 Recruitment will commence March 2023 at the Karolinska Comprehensive Cancer Centre, Sweden.  
322 Further participating sites will be added according to interest and need. Patient enrolment is  
323 estimated to be completed by the end of 2025, and first results on the primary endpoint are reported  
324 in 2026.

325

### 326 **Discussion**

327 The current standard of care for treatment of metastatic or irresectable triple negative breast cancer  
328 is the combination of ICIs with a chemotherapy backbone for patients with a PD-L1 positive tumor  
329 biopsy with the SP142 (for atezolizumab) or 2CC3 IHC antibodies (pembrolizumab) (1-4), leading to an  
330 improved overall survival compared to chemotherapy alone.

331 There is a clear clinical need to improve the selection of patients for this treatment combination to  
332 optimize the risk-benefit balance at an individual and societal level, as several downsides exist with the  
333 currently used reference standard therapy-predictive biomarker of PD-L1 IHC. This relates amongst  
334 others to the need for invasive tumor biopsies which are burdensome for patients and sometimes  
335 practically not feasible, the discordance in PD-L1 status between (different sites of) metastases and  
336 primary tumors and the limited representation of the results of a tumor biopsy from a solitary disease  
337 localisation compared to the whole-body burden of disease.

338 PET-imaging with tracers representing the targets of treatment is a possible way to evade these  
339 limitations and enables a real-time assessment of the target expression in the whole body which can  
340 be repeated when needed.

341 <sup>89</sup>Zr-atezolizumab is the first radiolabelled PD-L1 PET-tracer that has been evaluated. Warranting  
342 results from the first in human study provide the rationale for the MIMIR-mTNBC trial, where we  
343 hypothesize that PD-L1 PET imaging with <sup>89</sup>Zr-atezolizumab may be a more reliable and patient-  
344 friendly alternative to the current reference standard with PD-L1 IHC on a tumor biopsy. In addition,  
345 studying whole body expression of PD-L1 is thought to provide an enhanced insight in tumor biology  
346 and development of response to treatment as well as immune-mediated toxicity. This was very  
347 recently very elegantly shown in a clinical trial with a <sup>89</sup>Zr-labeled CD8 tracer <sup>89</sup>ZrED88082A, where a  
348 CD8-PET was done prior to and after 30 days of treatment with ICI (19). An enormous heterogeneity in  
349 CD8<sup>+</sup> T cell distribution and pharmacodynamics within and between patients was noted, revealing and  
350 visualizing the effects of ICIs on T-cell recruitment throughout the body.

351 A few trials with <sup>89</sup>Zr-atezolizumab have been initiated, according to a search at the website  
352 Clinicaltrials.gov (searched February 14<sup>th</sup> 2023); NCT04006522 in patient with metastatic renal cell

353 carcinoma, NCT03850028 in patients with malignant lymphomas and NCT05404048 in patients  
354 treated with CAR T-cell therapy. One imaging sub-study to a clinical trial in patients with metastatic  
355 lobular breast cancer with <sup>89</sup>Zr-atezolizumab has been registered at [clinicaltrials.gov](https://clinicaltrials.gov) (NCT04222426);  
356 the main study was terminated after including only one patient.  
357 Several imaging trials with other radiolabelled PD-L1 and PD-1 antibodies are currently ongoing in  
358 different patient cohorts; <sup>89</sup>Zr-pembrolizumab (active trials: NCT02760225, NCT03065764), <sup>89</sup>Zr-  
359 durvalumab (NCT03610061, NCT03829007) and <sup>89</sup>Zr-avelumab (NCT03514719).

360

361 Taken together, PET-imaging of PD-L1 and PD1 expression as well as other mediators in the response  
362 to ICIs may augment insights in the mechanisms of response to these drugs. In addition, this may  
363 provide a real-time whole-body assessment of the target of treatment and thereby be used as a  
364 therapy-predictive biomarker. The results of the MIMIR-mTNBC may add in the body of evidence of  
365 this area, with the prime focus to investigate whether the PD-L1 status by PET correlates to the PD-L1  
366 status determined with IHC on a tumor biopsy, which is the current standard of care for patients with  
367 mTNBC.

368

369 In conclusion, in the MIMIR-mTNBC trial, we aim to compare the level of statistical agreement  
370 between the current reference standard to assess PD-L1, i.e., on a tumor biopsy by means of IHC, to  
371 the experimental method of PD-L1 PET imaging with <sup>89</sup>Zr-atezolizumab. Our academic-initiated trial  
372 addresses a highly unmet medical need and may open new applications for superior and specific non-  
373 invasive tumor characterization. If <sup>89</sup>Zr-atezolizumab PET/CT demonstrates a sensitivity and specificity  
374 rate at least equal to the currently used reference method (IHC) it should impact patient management  
375 by selecting optimal patients for treatment with ICIs. In addition, such a precision medicine tool will  
376 substantially benefit the health economy by reduce cost for expensive therapies in patients without  
377 expected benefit and only side effects.

378

379 **Acknowledgements**

380 The study team is thankful for the scientific input from Professor E.G.E. de Vries from the University

381 Medical Center in Groningen, the Netherlands and the material support from Roche. The

382 administrative support of the Clinical Trials Office at the Karolinska University hospital, Stockholm

383 Sweden is greatly acknowledged.

384

385



## 386 References

- 387 1. Schmid P, Adams S, Rugo HS et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-  
388 Negative Breast Cancer. *NEJM* 2018;379(22):2108-2121.
- 389 2. Emens LA, Adams S, Barrios CH. First-line atezolizumab plus nab-paclitaxel for unresectable,  
390 locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall  
391 survival analysis. *Ann Oncol* 2021 Aug;32(8):983-993.
- 392 3. Cortes J, Cescon JW, Rugo HS et al. Pembrolizumab plus chemotherapy versus placebo plus  
393 chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-  
394 negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase  
395 3 clinical trial. *Lancet*, 396(10265):1817-1828
- 396 4. Cortes J, Rugo HS, Cescon DW et al. Pembrolizumab plus Chemotherapy in Advanced Triple-  
397 Negative Breast Cancer. *N Engl J Med* 2022; 387:217-226
- 398 5. Paver EC, Cooper WA, Colebatch AJ et al. Programmed death ligand-1 (PD-L1) as a predictive  
399 marker for immunotherapy in solid tumours: a guide to immunohistochemistry  
400 implementation and interpretation. *Pathology* 2021 Feb;53(2):141-156.
- 401 6. Lu S, Stein JE, Rimm DL et al. Comparison of Biomarker Modalities for Predicting Response to  
402 PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. *JAMA Oncol.*  
403 2019;5(8):1195-1204.
- 404 7. Chen N, Higashiyama N, Hoyos V. Predictive Biomarkers of Immune Checkpoint Inhibitor  
405 Response in Breast Cancer: Looking beyond Tumoral PD-L1. *Biomedicines* 2021 Dec  
406 8;9(12):1863
- 407 8. Boman C, Zerdes I, Mårtensson K et al. Discordance of PD-L1 status between primary and  
408 metastatic breast cancer: A systematic review and meta-analysis. *Cancer Treat Rev.* 2021  
409 Sep;99:102257.
- 410 9. Schmid P, Cortes J, Pusztai L et al. Pembrolizumab for Early Triple-Negative Breast Cancer. *N*  
411 *Engl J Med* 2020; 382:810-821,

- 412 10. Federal Drug Administration, approval Cerianna (18-  
413 FES) [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/212155s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf) Vd  
414 Donk PP, Kist de Ruijter L, Lub-de Hooge N et al. Molecular imaging biomarkers for immune  
415 checkpoint inhibitor therapy. *Theranostics* 2020; 10(4): 1708-1718.
- 416 11. Bensch F, van der Veen EL, Lub-de Hooge MN, et al. 89Zr-atezolizumab imaging as a non-  
417 invasive approach to assess clinical response to PD-L1 blockade in cancer. *Nature Medicine*,  
418 2018, 1852-
- 419 12. Bian et al, Survival benefit of platinum-based regimen in early stage triple negative breast  
420 cancer: A meta-analysis of randomized controlled trials. *NPJ Breast Cancer* 2021 Dec  
421 21;7(1):157.
- 422 13. West et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced  
423 squamous NSCLC (Impower131): results from a randomized phase III trial. *Lancet Oncology*  
424 2019 Jul;20(7):924-937
- 425 14. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours:  
426 revised RECIST guideline (version 1.1). *Eur J Cancer* 2009 Jan;45(2):228-47.
- 427 15. Raimondi L, Spinelli GP, Ciraci P et al. Prediction of Response to Atezolizumab Plus Nab-  
428 Paclitaxel in Unresectable Locally Advanced Triple Negative Breast Cancer (TNBC): the  
429 Clinical Usefulness of PD-L1 mRNA Expression in Plasma-Derived Exosomes. *Preprints 2021*,  
430 2021030777 (doi: 10.20944/preprints202103.0777.v1)
- 431 16. Gopalakrishnan C, Spencer CN, Nezi L et al. Gut microbiome modulates response to anti-PD-1  
432 immunotherapy in melanoma patients. *Science* 2018 Jan 5;359(6371):97-103. d
- 433 17. Zitvogel L, Ma Y, Raoult D et al, The microbiome in cancer immunotherapy: Diagnostic tools  
434 and therapeutic strategies. *Science*. 2018 Mar 23;359(6382):1366-1370.
- 435 18. Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS et al. Whole-body CD8<sup>+</sup> T cell  
436 visualization before and during cancer immunotherapy: a phase 1/2 trial. *Nat Med*. 2022  
437 Dec;28(12):2601-2610.

438 **Tables and Figures**

439 Figure 1. SPIRIT schedule of enrolment, interventions and assessments in the MIMIR-mTNBC trial.

440

441 *Abbreviations: programmed death ligand 1 (PD-L1), Positron Emission Tomography with Computed*

442 *Tomography (PET/CT), progressive disease (PD)*

443

444 Figure 2: Study design of the MIMIR-mTNBC trial.

445

446 *Abbreviations: metastatic triple negative breast cancer (mTNBC), programmed death ligand 1 (PD-L1),*

447 *Positron Emission Tomography with Computed Tomography (PET/CT), immunohistochemistry (IHC),*

448 *area under the curve (AUC).*

449

450 Table 1. Inclusion and exclusion criteria in the MIMIR-mTNBC trial.

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none"> <li>• Age ≥ 18 years</li> <li>• Diagnosed with mTNBC (tumor biology: ER&lt;10%, PR&lt;10%, HER2-)</li> <li>• Measurable disease according to RECIST v1.1</li> <li>• At least one metastatic lesion accessible for biopsy</li> <li>• Deemed by treating physician as fit for systemic therapy according to study protocol</li> <li>• ECOG performance score 0 or 1</li> <li>• Adequate blood tests for bone marrow, renal and hepatic functions (Table 6)</li> <li>• Able and willing to provide written informed consent</li> </ul>	<ul style="list-style-type: none"> <li>• Previous treatment with chemotherapy or targeted therapy for mTNBC. Radiation therapy and previous chemotherapy (including taxanes) in the context of curative therapy (if treatment was completed ≥12 months before randomization) is allowed.</li> <li>• Contraindications for PET/CT as defined for clinical practice</li> <li>• Other malignancy within the past five years</li> <li>• For women in childbearing age: pregnancy or lactation, or inadequate contraception</li> <li>• Uncontrolled hypertension, heart-, liver-, or kidney-diseases or other medical/psychiatric disorders</li> <li>• History of autoimmune disease with the exception of controlled hypothyroidism, type 1 diabetes mellitus or skin diseases.</li> <li>• Treatment with systemic immunosuppressive drugs</li> </ul>

451

452

453 Table 2: Objectives and endpoints of the MIMIR-mTNBC trial.

	Objectives	Endpoints
<i>Primary</i>	Establish the statistical agreement (by means of Cohen's kappa coefficient) between PD-L1 status by the experimental method (PET/CT with <sup>89</sup> Zr-atezolizumab) and the current reference standard (IHC on a tumor biopsy or resection specimen).	Level of statistical agreement by means of Cohen's kappa coefficient between PD-L1 IHC (positive defined as expression ≥1% on immune cells with SP142) and PD-L1 PET/CT (PD-L1 positivity is defined as having at least one lesion with radiotracer uptake over the background uptake).
<i>Secondary</i>	Evaluate the therapy-predictive value of <sup>89</sup> Zr-atezolizumab PET/CT, compared to the current reference standard (PD-L1 IHC) for treatment with nab-paclitaxel, carboplatin + atezolizumab. Three patient groups are defined, and treatment outcomes (progression free survival, disease response rate, treatment discontinuation rates) will be compared: <ol style="list-style-type: none"> <li>1) IHC positive and PET positive,</li> <li>2) IHC positive and PET negative,</li> <li>3) IHC negative and PET positive.</li> </ol>	Progression free survival, disease response rate and treatment discontinuation rates in three patient groups IHC positive and PET positive, IHC positive and PET negative, IHC negative and PET positive.
	Investigate inter- and intra-lesional differences in PD-L1 positivity by <sup>89</sup> Zr-atezolizumab radiotracer uptake	Discordance in <sup>89</sup> Zr-atezolizumab between different sites and within metastatic sites in the body.
	Investigate the therapeutic role of atezolizumab for ER-low, PD-L1 positive breast cancer (ER expression 1-10%).	Progression free survival, disease response rate and treatment discontinuation rates in patients with ER-low mBC treated with nab-paclitaxel, carboplatin and atezolizumab.
	Investigate the possible role of <sup>89</sup> Zr-atezolizumab PET/CT as a method of detecting otherwise (with regular CT-chest-abdomen) occult metastatic sites including sanctuary sites such as the central nervous system (CNS)	Percentage of <sup>89</sup> Zr-atezolizumab uptake in sites, not previously determined on the routine radiological investigation with CT, as a measure of cancer spread determined on whole body <sup>89</sup> Zr-atezolizumab PET/CT in and different metastases.
<i>Exploratory</i>	Explore mechanisms for possible discordance between PD-L1 positivity by IHC and <sup>89</sup> Zr-atezolizumab radiotracer uptake on PET/CT	Differences in immune infiltrate and tumor cells in biopsied sites with discordance between PD-L1 IHC and PD-L1 PET
	Study the genetic profile of circulating (fractions of) tumour cells to predict treatment responses and monitor changes in biological behaviour by means of ctDNA assessed by Foundation One liquid biopsies CDx-analysis at baseline and at the first treatment evaluation, with a specific focus on identifying patients with an enriched 'Immunotherapy pathway' in relation to PD-L1 status on PET and IHC and levels of circulating PD-L1 mRNA measured in exosomes at baseline and the first treatment evaluation	Levels and composition of circulating biomarkers and relation to treatment response (PFS, disease response rate) and PD-L1 positivity by PET and IHC <ul style="list-style-type: none"> <li>- Levels of circulating PD-L1 mRNA</li> <li>- Gene expression signals in liquid biopsies</li> </ul>
	Explore off-target effects of ICI by means of studying <sup>89</sup> Zr-atezolizumab radiotracer uptake in organs at risk for immune-mediated toxicities as well as studying the composition of and changes in the intestinal microbiome.	Rates (and severity according to CTC-AE) of immune-mediated side effects in relation to <sup>89</sup> Zr-atezolizumab tracer uptake in organs at risk for immune-mediated toxicities.

454



# MIMIR-mTNBC

